Bollé Safety, the PPE Eyewear Specialists Introduce Go Green: Concrete Actions to Protect the Environment
25.5.2021 11:45:00 EEST | Business Wire | Press release
Bollé Safety wants to do its part to protect the planet. In 2021, the global brand for eye protection is kicking into high gear with their Go Green plan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210525005026/en/
Sustainability: a long-term process
Bollé Safety’s products have been packaged in recyclable BPA-free plastic bags since 2005. But as a company selling millions of units annually, they wish to do more on every aspect of their production and distribution processes.
With the Go Green program, all of their eco-friendly improvements add up to reach one goal: become a certified B Corporation by 2023, and meet the most rigorous standards of environmental performance, for their stakeholders benefits.
Focusing on green research and development
Their R&D and production departments are committed to developing more environmentally-friendly materials, products and processes, while always preserving the quality and protection they offer.
Introducing the Ecopack: 100% recyclable packaging made from recycled cardboard and tissue paper. The user-instruction is printed directly on the overwrap with vegetal-based ink to avoid all plastic. By optimizing their product design, they also reduce the amount of raw material required during production, as well as the packaging weight. It produces 30% less waste than before, improving their carbon footprint during transportation.
More sustainable technologies and raw materials
Focus on eco-friendly products: SOLIS and KLASSEE. With its nylon frame made from 100% recycled fishing nets, SOLIS is EN166-compliant and embodies the company’s R&D effort towards sustainability. KLASSEE’s (prescription) bio-based frame is made from castor oil.
Extra efforts: By using the latest technologies, they also reduce energy consumption and waste production during manufacturing (injection, molding). Some of the coatings are water-based to reduce the use of chemicals when possible.
Sustainability has never been more necessary than today. It is time for action. This is the reason why Bollé Safety decided, as a company, to become more conscious.
To find out more about our actions, visit https://bit.ly/3vuHanQ
About Bollé Safety
Bollé Safety, the global brand for eye protection since 1888.
With a wide range of innovative, comfortable and protective safety and prescription eyewear, we are trusted with the protection of over 20 million workers’ vision in 100 countries. It is our duty to make a difference, for you and for the future of our Planet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005026/en/
Contact information
Press
Aline CAMPO/Robin SAUNIER-PLUMAZ
+33-(0)7-64-55-36-09/+33-(0)7-64-55-36-09
E-mail: press@bolle-safety.com
bolle-safety.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 05:36:00 EET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Access Advance Welcomes New VDP Pool Licensors and Releases Independent Economic Analysis Confirming FRAND Compliance24.3.2026 02:00:00 EET | Press release
Access Advance LLC today announced that Sharp Corporation, CB Cline, SK Planet, and Telechips, Inc have joined the Access Advance Video Distribution Patent Pool (VDP Pool) as Licensors, further expanding the pool's portfolio of patents for modern video codec technologies (HEVC, VVC, VP9, and AV1). The announcement coincides with the release of an independent economic analysis by Criterion Economics confirming that the VDP Pool's royalty structure is fair, reasonable, and nondiscriminatory (FRAND). Sharp, a global leader in consumer electronics and display technologies, brings decades of research and development in video processing and compression to the VDP Pool. The additions of CB Cline, SK Planet, and Telechips, Inc further expand the pool’s patent coverage. These additions reinforce the VDP Pool’s position as the leading licensing program for modern video codec technologies powering the streaming experiences of consumers worldwide. "Sharp, CB Cline, SK Planet, and Telechips each br
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom